31. The effect of elevated triglycerides and purified eicosapentaenoic acid ethyl ester (EPA) for cardiovascular risk reduction in the UK Biobank population. (25th November 2020) Authors: Radenkovic, D; Vakili, D; Botta, G; Boli, A; Banach, M; Bhatt, D.L Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
32. The effect of in-hospital high-dose vs. low-dose intensive statin in patients with non-ST segment elevation acute coronary syndrome. (25th November 2020) Authors: Chen, P; Liu, Y; Duan, C; Fan, H; Zeng, L; Guo, W; Jiang, L; Xue, W; He, W; Tao, S; Guo, Z; Chen, J; Tan, N; He, P Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
33. The prevalence of statin intolerance worldwide: a systematic review and meta-analysis with 4, 143, 517 patients. (14th October 2021) Authors: Bytyci, I; Bajraktari, G; Sahebkar, A; Penson, P E; Rysz, R; Banach, M Y Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
34. The results of 5-year atorvastatin therapy at the doses of 20–40 mg daily in metabolically compromised patients at very high risk. (25th November 2020) Authors: Korolyuk, O Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗